CARsgen Therapeutics Closes a USD 186 Million Series C Equity Financing to Accelerate Global Clinical Trials of its Cell Therapy Product Candidates

SHANGHAI, Nov. 2, 2020 -- (Healthcare Sales & Marketing Network) -- CARsgen Therapeutics Holdings Limited ("CARsgen"), a leading biotechnology company focused on innovation and development of chimeric antigen receptor (CAR) T-cell therapeutics, ... Biopharmaceuticals, Venture Capital CARsgen Therapeutics, CAR-T, cell therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news